USA - NASDAQ:HSIC - US8064071025 - Common Stock
The current stock price of HSIC is 63.2 USD. In the past month the price decreased by -5.71%. In the past year, price decreased by -10.19%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MCK | MCKESSON CORP | 24.23 | 100.91B | ||
| COR | CENCORA INC | 21.81 | 65.49B | ||
| CAH | CARDINAL HEALTH INC | 21.41 | 45.32B | ||
| AHCO | ADAPTHEALTH CORP | 29 | 1.22B | ||
| AHG | AKSO HEALTH GROUP | N/A | 889.76M | ||
| OMI | OWENS & MINOR INC | 2.72 | 306.64M | ||
| WGRX | WELLGISTICS HEALTH INC | N/A | 63.91M | ||
| ATPC | AGAPE ATP CORP | N/A | 60.01M | ||
| COSM | COSMOS HEALTH INC | N/A | 24.47M | ||
| VRAX | VIRAX BIOLABS GROUP LTD | N/A | 2.44M | ||
| POM | POMDOCTOR LTD - ADR | N/A | 640.76M |
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. The company is headquartered in Melville, New York and currently employs 25,000 full-time employees. Its segments consist of Global Distribution and Value-Added services, Global Specialty Services, and Global Technology. Global Distribution and Value-Added Services include the distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under its own brand, a portfolio of consumable merchandise. The Global Specialty Products includes the manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other healthcare-related products and services. Global Technology includes the development and distribution of practice management software, e-services, and other products.
HENRY SCHEIN INC
135 Duryea Rd
Melville NEW YORK 11747 US
CEO: Stanley M. Bergman
Employees: 25000
Phone: 16318435500
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. The company is headquartered in Melville, New York and currently employs 25,000 full-time employees. Its segments consist of Global Distribution and Value-Added services, Global Specialty Services, and Global Technology. Global Distribution and Value-Added Services include the distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other services. This segment also markets and sells under its own brand, a portfolio of consumable merchandise. The Global Specialty Products includes the manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other healthcare-related products and services. Global Technology includes the development and distribution of practice management software, e-services, and other products.
The current stock price of HSIC is 63.2 USD. The price increased by 0.48% in the last trading session.
HSIC does not pay a dividend.
HSIC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HSIC.
HENRY SCHEIN INC (HSIC) has a market capitalization of 7.66B USD. This makes HSIC a Mid Cap stock.
ChartMill assigns a fundamental rating of 4 / 10 to HSIC. HSIC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months HSIC reported a non-GAAP Earnings per Share(EPS) of 4.66. The EPS increased by 8.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.05% | ||
| ROA | 3.57% | ||
| ROE | 11.29% | ||
| Debt/Equity | 0.87 |
23 analysts have analysed HSIC and the average price target is 74.93 USD. This implies a price increase of 18.55% is expected in the next year compared to the current price of 63.2.
For the next year, analysts expect an EPS growth of 3.75% and a revenue growth 1.75% for HSIC